# Lightnix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lightnix

- Industry: Medical Devices & Equipment
- Headquarters: Soka-shi, Japan
- Website: www.lightnix.jp
- Total disclosed funding: $0.9M
- Latest round: Series C (Dec 17, 2021)
- Investors on record: 1

## About

Based in Japan, Lightnix Inc. specializes in developing environmentally friendly medical devices, offering innovative solutions for intradermal vaccine administration and addressing the need for patient-friendly medical technology.Lightnix Inc. is engaged in the development and manufacturing of medical devices and was founded in 2002 in Soka-shi, Japan. The firm has completed 6 deals, with the most recent funding round being a Series C on December 17, 2021, where it raised JPY 105 million from Universal Materials Incubator, bringing the total amount raised to JPY 105 million and a current valuation of JPY 710.665 million. The founder's background is not publicly detailed.Lightnix, Inc. specializes in the development and manufacturing of environmentally friendly medical devices, prominently featuring their flagship product, the PinniX Light. This device is a groundbreaking, plant-based lancet designed for intradermal vaccine administration. Its innovative design mimics the qualities of a mosquito, reducing pain during use and ensuring a soft, comfortable experience for patients. The PinniX Light promotes safe and effective blood sampling while emphasizing hygiene through its fully sealed, sterile individual packaging. The company targets healthcare providers, clinics, and vaccination centers globally, with a focus on markets in Europe, North America, and Asia, addressing the growing demand for safer and more patient-friendly medical devices.Lightnix generates revenue through the direct sale of its PinniX Light lancets to healthcare facilities and distributors. The transaction structure primarily operates on a B2B model, where bulk orders are placed by hospitals and clinics that utilize these devices for vaccination programs. The revenue stream is supported by partnerships with medical supply wholesalers who distribute the products to smaller healthcare providers. While specific pricing plans for the PinniX Light are not disclosed, the focus remains on providing high-quality, single-use devices that ensure safety and comfort, aligning with the growing emphasis on patient-centered care in the medical industry.In December 2021, Lightnix Inc. raised JPY 105 million in Series C funding from returning investor Universal Materials Incubator. The company plans to utilize this funding to continue the development of its device for intradermal administration of medicine. Future growth efforts include the design and launch of new products targeting specific healthcare needs and expanding into new markets, particularly in Europe, North America, and Asia, to meet increasing global demand.

## Funding rounds

- Series C, Dec 17, 2021, $0.9M — Universal Materials Incubator

## Investors

- Universal Materials Incubator (https://capitalatlas.ai/funds/universal-materials-incubator) — Series C